FUSION PROTEINS: APPLICATIONS AND CHALLENGES - Fusion Protein Technologies for Biopharmaceuticals: Applications and Challenges - page 19

36. Argos P. (1990) An investigation of oligopeptides linking
domains in protein tertiary structures and possible candi-
dates for general gene fusion. J. Mol. Biol. 211(4), 943-958.
37. Newton DL, Xue Y, Olson KA, Fett JW, Rybak SM. (1996)
Angiogenin single-chain immunofusions: influence of pep-
tide linkers and spacers between fusion protein domains.
Biochemistry 35(2), 545-553.
38. Arai R, Ueda H, Kitayama A, Kamiya N, Nagamune T.
(2001) Design of the linkers which effectively separate
domains of a bifunctional fusion protein. Protein Eng.
14(8), 529-532.
39. Zhao HL, Yao XQ, Xue C, Wang Y, Xiong XH, Liu ZM.
(2008) Increasing the homogeneity, stability and activity of
human serum albumin and interferon-alpha2b fusion pro-
tein by linker engineering. Protein Expr. Purif. 61(1),
73-77.
40. Xue F, Gu Z, Feng J. (2004) LINKER: a web server to
generate peptide sequences with extended conformation.
Nucleic Acids Res. 32(Web Server issue), W562-W565.
41. George RA, Heringa J. (2002) An analysis of protein domain
linkers: their classification and role in protein folding. Protein
Eng. 15(11), 871-879.
42. Chen X, Bai Y, Zaro JL, Shen W-C. (2010) Design of an
in vivo cleavable disulfide linker in recombinant fusion
proteins. BioTechniques 49(1), 513-518.
43. Bai Y, Shen W-C. (2006) Improving the oral efficacy of
recombinant granulocyte colony-stimulating factor and trans-
ferrin fusion protein by spacer optimization. Pharm. Res.
23(9), 2116-2121.
44. Amet N, Lee H-F, Shen W-C. (2009) Insertion of the designed
helical linker led to increased expression of tf-based fusion
proteins. Pharm. Res. 26(3), 523-528.
45. Goyal A, Batra JK. (2000) Inclusion of a furin-sensitive
spacer enhances the cytotoxicity of ribotoxin restrictocin
containing recombinant single-chain immunotoxins. Bio-
chem. J. 345(Pt 2), 247-254.
46. Chen T, Yang J, Wang Y, Zhan C, Zang Y, Qin J. (2005)
Design of recombinant stem cell factor-macrophage
colony stimulating factor fusion proteins and their biologi-
cal activity in vitro. J. Comput. Aided Mol. Des. 19(5),
319-328.
47. Won J, Nam P, Lee Y, Choe M. (2009) Higher cytotoxicity of
divalent antibody-toxins than monovalent antibody-toxins.
Biochem. Biophys. Res. Commun. 382(1), 15-20.
48. Liu M, Wang X, Yin C, Zhang Z, Lin Q, Zhen Y, et al. (2008)
A novel bivalent single-chain variable fragment (scFV) inhib-
its the action of tumour necrosis factor a . Biotechnol. Appl.
Biochem. 50(4), 173.
49. de Kruif J, Logtenberg T. (1996) Leucine zipper dimerized
bivalent and bispecific scFv antibodies from a semi-synthetic
antibody phage display library. J. Biol. Chem. 271(13), 7630-
7634.
50. Hoyne PA, Cosgrove LJ, McKern NM, Bentley JD, Ivancic N,
Elleman TC, et al. (2000) High affinity insulin binding by
soluble insulin receptor extracellular domain fused to a
leucine zipper. FEBS Lett. 479(1-2), 15-18.

51. Morris NP, Peters C, Montler R, Hu H-M, Curti BD, Urba WJ,
et al. (2007) Development and characterization of recombi-
nant human Fc:OX40L fusion protein linked via a coiled-coil
trimerization domain. Mol. Immunol. 44(12), 3112-3121.
52. Rozanov DV, Savinov AY, Golubkov VS, Rozanova OL,
Postnova TI, Sergienko EA, et al. (2009) Engineering a
leucine zipper-TRAIL homotrimer with improved cyto-
toxicity in tumor cells. Mol. Cancer Ther. 8(6), 1515-1525.
53. Spitzer D, McDunn JE, Plambeck-Suess S, Goedegebuure
PS, Hotchkiss RS, Hawkins WG. (2010) A genetically
encoded multifunctional TRAIL trimer facilitates cell-
specific targeting and tumor cell killing. Mol. Cancer Ther.
9(7), 2142-2151.
54. Krippner-Heidenreich A, Grunwald I, Zimmermann G,
Kuhnle M, Gerspach J, Sterns T, et al. (2008) Single-chain
TNF, a TNF derivative with enhanced stability and antitu-
moral activity. J. Immunol. 180(12), 8176-8183.
55. Berg D, Lehne M, Muller N, Siegmund D, Munkel S, Sebald
W, et al. (2007) Enforced covalent trimerization increases the
activity of the TNF ligand family members TRAIL and
CD95L. Cell Death Differ. 14(12), 2021-2034.
56. Stone GW, Barzee S, Snarsky V, Kee K, Spina CA, Yu X-F, et
al. (2006) Multimeric soluble CD40 ligand and GITR ligand
as adjuvants for human immunodeficiency virus DNA vac-
cines. J. Virol. 80(4), 1762-1772.
57. Holler N, Tardivel A, Kovacsovics-Bankowski M, Hertig S,
Gaide O, Martinon F, et al. (2003) Two adjacent trimeric Fas
ligands are required for Fas signaling and formation of a
death-inducing signaling complex. Mol. Cell. Biol. 23(4),
1428-1440.
58. Sanchez-Arevalo Lobo VJ, Cuesta AM, Sanz L, Compte M,
Garc ıa P, Prieto J, et al. (2006) Enhanced antiangiogenic
therapy with antibody-collagen XVIII NC1 domain fusion
proteins engineered to exploit matrix remodeling events. Int.
J. Cancer 119(2), 455-462.
59. Fan C-Y, Huang C-C, Chiu W-C, Lai C-C, Liou G-G, Li H-C,
et al. (2008) Production of multivalent protein binders using a
self-trimerizing collagen-like peptide scaffold. FASEB J.22
(11), 3795-3804.
60. Rohn J. (2010) Newsmaker: anaphore. Nat. Biotechnol.
28(11), 1143.
61. Onda M, Beers R, Xiang L, Nagata S, Wang Q-C, Pastan I.
(2008) An immunotoxin with greatly reduced immunogenic-
ity by identification and removal of B cell epitopes. Proc.
Natl. Acad. Sci. USA 105(32), 11311-11316.
62. Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R.
(2011) Immunotoxins with decreased immunogenicity and
improved activity. Leuk. Lymphoma 52(Suppl. 2), 87-90.
63. Harding FA, Liu AD, Stickler M, Razo OJ, Chin R, Faravashi
N, et al. (2005) A beta-lactamase with reduced immunoge-
nicity for the targeted delivery of chemotherapeutics using
antibody-directed enzyme prodrug therapy. Mol. Cancer
Ther. 4(11), 1791-1800.
64. Liang Y, Qiu H, Glinka Y, Lazarus AH, Ni H, Prud'homme
GJ, et al. (2011) Immunity against a therapeutic xenopro-
tein/Fc construct delivered by gene transfer is reduced